Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

1095506

USP

Carbidopa

United States Pharmacopeia (USP) Reference Standard

Sinônimo(s):

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C10H14N2O4 · H2O
Número CAS:
38821-49-7
Peso molecular:
244.24
Número MDL:
MFCD00889211
Código UNSPSC:
41116107
ID de substância PubChem:
329749233
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

carbidopa

fabricante/nome comercial

USP

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1

chave InChI

QTAOMKOIBXZKND-PPHPATTJSA-N

Informações sobre genes

human ... DDC(1644)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Carbidopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Extended-Release Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Tablets

Nota de análise

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Outras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302,H319

Classificações de perigo

Acute Tox. 4 Oral - Eye Irrit. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 2

1 of 2

3,4-Dihydroxy-L-phenylalanine ≥98% (TLC)

Sigma-Aldrich

D9628

3,4-Dihydroxy-L-phenylalanine

Dopamina

Sigma-Aldrich

H8502

Dopamina

Q. Alan Xu, Timothy L. Madden
Analytical Methods for Therapeutic Drug Monitoring and Toxicology, 80-80 (2011)
Mohseni Mehran S M et al.
Journal of clinical and diagnostic research : JCDR, 7(6), 1004-1007 (2013-08-02)
According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson's disease. The addition of Carbidopa (C-dopa) can reduce
Robert A Hauser
Expert review of neurotherapeutics, 12(2), 133-140 (2012-02-01)
Levodopa (LD) remains the most effective medication to treat Parkinson's disease (PD). However, most patients develop motor fluctuations and dyskinesias with long-term LD use. It is thought that these response complications are due, at least in part, to LD's short
J T Hutton et al.
Neurology, 42(1 Suppl 1), 51-56 (1992-01-01)
Parkinson's disease patients treated chronically with levodopa often develop fluctuations in motor response. Motor fluctuations can be attributed in part to oscillating plasma levodopa concentrations. A controlled-release formulation containing 200 mg of levodopa and 50 mg of carbidopa provides superior
A Castro et al.
Neurologia (Barcelona, Spain), 20(4), 180-188 (2005-05-14)
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa. These problems and experimental data in cell cultures indicating a neurotoxic effect of levodopa have led
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica